178 related articles for article (PubMed ID: 34913599)
1. Impact of Barrett oesophagus diagnoses and endoscopies on oesophageal cancer survival in the UK: A cohort study.
Offman J; Pesola F; Fitzgerald RC; Hamilton W; Sasieni P
Cancer Med; 2022 Feb; 11(4):1160-1171. PubMed ID: 34913599
[TBL] [Abstract][Full Text] [Related]
2. Incidence of adenocarcinoma and mortality in patients with Barrett's oesophagus diagnosed between 1976 and 1986: implications for endoscopic surveillance.
Rana PS; Johnston DA
Dis Esophagus; 2000; 13(1):28-31. PubMed ID: 11005328
[TBL] [Abstract][Full Text] [Related]
3. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
4. A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis.
Caygill CP; Reed PI; Johnston BJ; Hill MJ; Ali MH; Levi S
Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1355-8. PubMed ID: 10654794
[TBL] [Abstract][Full Text] [Related]
5. [Surveillance for Barrett's oesophagus: worthwhile?].
Kastelein F; Kuipers EJ
Ned Tijdschr Geneeskd; 2012; 156(49):A5497. PubMed ID: 23218039
[TBL] [Abstract][Full Text] [Related]
6. Length of Barrett's oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma.
Pohl H; Pech O; Arash H; Stolte M; Manner H; May A; Kraywinkel K; Sonnenberg A; Ell C
Gut; 2016 Feb; 65(2):196-201. PubMed ID: 26113177
[TBL] [Abstract][Full Text] [Related]
7. Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study.
Bhat SK; McManus DT; Coleman HG; Johnston BT; Cardwell CR; McMenamin U; Bannon F; Hicks B; Kennedy G; Gavin AT; Murray LJ
Gut; 2015 Jan; 64(1):20-5. PubMed ID: 24700439
[TBL] [Abstract][Full Text] [Related]
8. Does Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies?
Kunzmann AT; Coleman HG; Johnston BT; Turkington RC; McManus D; Anderson LA; Thrift AP
Dig Dis Sci; 2021 Jun; 66(6):1965-1973. PubMed ID: 32734400
[TBL] [Abstract][Full Text] [Related]
9. Barrett oesophagus and adenocarcinoma: an overview of epidemiologic, conceptual and clinical issues.
van Sandick JW; van Lanschot JJ; Tytgat GN; Offerhaus GJ; Obertop H
Scand J Gastroenterol Suppl; 2001; (234):51-60. PubMed ID: 11768562
[TBL] [Abstract][Full Text] [Related]
10. Surveillance of Barrett's columnar-lined oesophagus in the UK: endoscopic intervals and frequency of detection of dysplasia.
Ramus JR; Gatenby PA; Caygill CP; Winslet MC; Watson A
Eur J Gastroenterol Hepatol; 2009 Jun; 21(6):636-41. PubMed ID: 19177028
[TBL] [Abstract][Full Text] [Related]
11. A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance.
Gudlaugsdottir S; van Blankenstein M; Dees J; Wilson JH
Eur J Gastroenterol Hepatol; 2001 Jun; 13(6):639-45. PubMed ID: 11434588
[TBL] [Abstract][Full Text] [Related]
12. Review article: Barrett's oesophagus and associated adenocarcinoma--a UK perspective.
Fitzgerald RC
Aliment Pharmacol Ther; 2004 Dec; 20 Suppl 8():45-9. PubMed ID: 15575873
[TBL] [Abstract][Full Text] [Related]
13. The path(ology) from reflux oesophagitis to Barrett oesophagus to oesophageal adenocarcinoma.
Salimian KJ; Birkness-Gartman J; Waters KM
Pathology; 2022 Mar; 54(2):147-156. PubMed ID: 34711413
[TBL] [Abstract][Full Text] [Related]
14. Oesophageal adenocarcinoma and Barrett's oesophagus.
Das M
Lancet Oncol; 2016 Dec; 17(12):e524. PubMed ID: 27818151
[No Abstract] [Full Text] [Related]
15. The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off.
Masclee GM; Coloma PM; de Wilde M; Kuipers EJ; Sturkenboom MC
Aliment Pharmacol Ther; 2014 Jun; 39(11):1321-30. PubMed ID: 24738722
[TBL] [Abstract][Full Text] [Related]
16. Surveillance for Barrett's oesophagus: results from a programme in Northern Ireland.
Murphy SJ; Dickey W; Hughes D; O'Connor FA
Eur J Gastroenterol Hepatol; 2005 Oct; 17(10):1029-35. PubMed ID: 16148547
[TBL] [Abstract][Full Text] [Related]
17. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.
Fitzgerald RC; di Pietro M; O'Donovan M; Maroni R; Muldrew B; Debiram-Beecham I; Gehrung M; Offman J; Tripathi M; Smith SG; Aigret B; Walter FM; Rubin G; ; Sasieni P
Lancet; 2020 Aug; 396(10247):333-344. PubMed ID: 32738955
[TBL] [Abstract][Full Text] [Related]
18. A surveillance programme for Barrett's oesophagus in a UK general hospital.
Olithselvan A; Gorard DA; McIntyre AS
Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
[TBL] [Abstract][Full Text] [Related]
19. Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
Gatenby P; Caygill C; Wall C; Bhatacharjee S; Ramus J; Watson A; Winslet M
World J Gastroenterol; 2014 Jul; 20(28):9611-7. PubMed ID: 25071359
[TBL] [Abstract][Full Text] [Related]
20. Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients.
Tan MC; Mansour N; White DL; Sisson A; El-Serag HB; Thrift AP
Aliment Pharmacol Ther; 2020 Jul; 52(1):20-36. PubMed ID: 32452599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
